Infectious Diseases (COVID-19 Access Restrictions and Clearance) (Amendment No. 12) Regulations 2022

Status:

Published in Subsidiary Legislation Supplement
on 28 Jul 2022

No. S 634

Infectious Diseases Act 1976

Infectious Diseases
(COVID-19 Access Restrictions and Clearance)
(Amendment No. 12) Regulations 2022

In exercise of the powers conferred by section 73(1) of the Infectious Diseases Act 1976, the Minister for Health makes the following Regulations:

Citation and commencement

1. These Regulations are the Infectious Diseases (COVID‑19 Access Restrictions and Clearance) (Amendment No. 12) Regulations 2022 and come into operation on 29 July 2022.

Amendment of regulation 2

2. In regulation 2(1) of the Infectious Diseases (COVID‑19 Access Restrictions and Clearance) Regulations 2021 (G.N. No. S 273/2021) (called in these Regulations the principal Regulations) —

(a)

after the definition of “Control Order”, insert —

“ “corresponding foreign authority” means the government or an appropriate authority of a foreign country that has the functions corresponding to the functions of —

(a)

the Director —

(i)	under these Regulations of certifying that an individual has recovered from a COVID‑19 infection in that foreign country;
(ii)	under the Infectious Diseases (Antigen Rapid Test Providers) Regulations 2021 of authorising a person to provide in that foreign country the services of an approved test provider; or
(iii)	under the Private Hospitals and Medical Clinics Act 1980 of authorising any premises or conveyance in that foreign country to be used as a private hospital, medical clinic, clinical laboratory or healthcare establishment; or

(b)

the Singapore Medical Council under the Medical Registration Act 1997 of authorising an individual to practise medicine in that foreign country;”;

(b)

after the definition of “entrant”, insert —

“ “foreign ART provider” means a person who is duly authorised by a corresponding foreign authority of a foreign country to provide in the foreign country the services of an approved test provider;

“foreign country” means any country or territory outside Singapore;

“foreign healthcare institution” means any premises or conveyance that is duly authorised by a corresponding foreign authority of a foreign country to be used as a private hospital, medical clinic, clinic laboratory or healthcare establishment in the foreign country;

“foreign medical practitioner” means an individual who is duly authorised by a corresponding foreign authority of a foreign country to practise medicine in that foreign country;”;

(c)

replace the definition of “recovered individual” with —

“ “recovered individual” means an individual who —

(a)

tests positive for SARS‑CoV‑2 upon undergoing (whether before, on or after 24 April 2021) any of the following:

(i)	a polymerase chain reaction test in or outside Singapore;
(ii)	an antigen rapid test in Singapore on or after 6 January 2022, and a subsequent serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection;
(iii)	an antigen rapid test outside Singapore, where the result is certified by a corresponding foreign authority, foreign medical practitioner, foreign healthcare institution or foreign ART provider;
(iv)	an antigen rapid test outside Singapore (where the result is not certified in accordance with sub‑paragraph (iii)), and a subsequent serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection;
(v)	a serology test in or outside Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection, without having tested positive for SARS‑CoV‑2 upon undergoing a polymerase chain reaction test or an antigen rapid test;
(vi)	an antigen rapid test in Singapore on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms;
(vii)	an antigen rapid test in Singapore (whether before, on or after 23 February 2022) that is performed by or under the direction of an approved test provider or is self‑administered by the individual under the supervision of an approved test provider;

(b)

is assessed (whether before, on or after 24 April 2021) as having had a COVID‑19 infection; and

(c)

is not actively infected with a COVID‑19 infection;”;

(d)

after the definition of “relevant sampling activity”, insert —

“ “relevant start date”, in relation to any COVID‑19 infection of a recovered individual, means —

(a)

in a case falling within paragraph (a)(v) of the definition of “recovered individual” read with paragraphs (b) and (c) of that definition —

(i)	the date that the individual first tested positive for SARS‑CoV‑2 upon undergoing the serology test in or outside Singapore that led to the assessment of the individual having the COVID‑19 infection; or
(ii)	such earlier date (if any) that is certified by a registered medical practitioner in Singapore as the date that the individual is first assessed as having had the COVID‑19 infection; or

(b)

in any other case — the date that the individual first tested positive for SARS‑CoV‑2 upon undergoing the test or series of tests under paragraph (a)(i), (ii), (iii), (iv), (vi), or (vii) of the definition of “recovered individual”, which led to the assessment of the individual having the COVID‑19 infection;”;

(e)

in the definition of “Type S recovered individual”, replace “paragraph (a)(iii)” with “paragraph (a)(v)”; and

(f)

in the definition of “Type T recovered individual”, replace “paragraph (a)(i), (ii), (iv) or (v)” with “paragraph (a)(i), (ii), (iii), (iv), (vi) or (vii)”.

Amendment of regulation 6

3. In regulation 6 of the principal Regulations —

(a)

in paragraph (2)(a), replace sub-paragraph (i) with —

“(i)	starting on the relevant start date for the COVID‑19 infection; and”;

(b)

in paragraph (2)(b), after the words “as having a COVID‑19 infection”, insert “upon undergoing the test or series of tests under paragraph (a)(i), (ii), (iii), (iv), (vi) or (vii) of the definition of “recovered individual”,”;

(c)

in paragraph (2)(b), replace sub-paragraph (i) with —

“(i)	starting on the relevant start date for that COVID‑19 infection; and”;

(d)

in paragraph (5)(a), replace sub-paragraph (ii) with —

“(ii)

180 days, starting on the relevant start date for the last infection;”;

(e)

in paragraph (5), replace sub‑paragraphs (b) and (c) with —

“(b)

if the recovered individual was granted a certificate under paragraph (4) stating that the individual has a cleared status (general) for a period of 120 days — for a period of 270 days starting on the relevant start date for that infection;

(c)

if the recovered individual was granted a certificate under paragraph (3)(d) — for a period starting on the relevant start date for the last infection and ending on the later of the following:

(i)	the last day of the period mentioned in paragraph (3)(d);
(ii)	the 180th day.”; and

(f)

in paragraph (5A), replace sub-paragraph (b) with —

“(b)	in the case of paragraph (5)(b) — the other dose is administered at least 86 days after the relevant start date for that infection.”.

Amendment of First Schedule

4. In the following provisions of the First Schedule to the principal Regulations, replace “the recovered individual first tested positive for SARS‑CoV‑2” with “the relevant start date for the COVID‑19 infection concerned”:

Item 1, in the second column, in paragraph (1)

Item 2, in the second column, in paragraph (1)

Item 3, in the second column, in paragraph (1)

Item 4, in the second column, in paragraph (1)

Item 5, in the second column, in paragraphs (1), (3) and (5)

Item 6, in the second column, in paragraphs (1), (3), (4) and (7)

Item 7, in the second column, in paragraph (1)

Item 8, in the second column, in paragraph (1)

Item 9, in the second column, in paragraph (1).

[G.N. Nos. S 310/2021; S 324/2021; S 367/2021;S 396/2021; S 513/2021; S 542/2021; S 590/2021;S 620/2021; S 682/2021; S 768/2021; S 774/2021;S 863/2021; S 908/2021; S 991/2021; S 9/2022;S 49/2022; S 69/2022; S 91/2022; S 102/2022;S 180/2022; S 226/2022; S 317/2022; S 326/2022;S 445/2022; S 474/2022]

Made on 28 July 2022.

NG HOW YUE

Permanent Secretary
(Health Development),
Ministry of Health,
Singapore.

[AG/LEGIS/SL/137/2020/13 Vol. 4]

Search within Legislation